Literature DB >> 3494876

Potent effects of the monoclonal antibody-mitomycin C conjugate on human colon cancers.

H Kotanagi, K Fukuda, N Ogata, M Takahashi, T Masuda, K Koyama, T Takahashi.   

Abstract

The effects of the monoclonal antibody-mitomycin C conjugate against human colon cancers were studied, in vitro and in vivo. Mitomycin C (MMC) was conjugated with the human colon cancer-specific monoclonal antibody, using a cyanogen bromide method. The effect of the conjugate and free MMC, in vitro, was measured by incubation with human colon cancer SW1116 cells. The MMC concentration of the conjugate and of free MMC needed for 50 per cent killing of target cells was 0.11 microgram/ml and 7.00 micrograms/ml, respectively. The effect of the conjugate and of free MMC, in vivo, was assayed by the growth inhibition of human colon cancer xenografted in nude mice, after intraperitoneal injections of 30 micrograms MMC/kg. Antitumor effects of the conjugate against the cancer in nude mice were significantly more potent than that of free MMC.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3494876     DOI： 10.1007/BF02470585

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN： 0047-1909


  9 in total

1.  Pharmacology of mitomycin C. I. Toxicity and pathologic effects.

Authors:  F S PHILIPS; H S SCHWARTZ; S S STERNBERG
Journal:  Cancer Res       Date:  1960-10       Impact factor: 12.701

2.  Clinical experience with mitomycin C in large infrequent doses.

Authors:  T E Godfrey; D W Wilbur
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

3.  Antitumor activity of timed-release derivative of mitomycin C, agarose bead conjugate.

Authors:  T Kojima; M Hashida; S Muranishi; H Sezaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1978-06       Impact factor: 1.645

4.  The preparation of mitomycin C, adriamycin and daunomycin covalently bound to antibodies as improved cancer chemotherapeutic agents.

Authors:  T Suzuki; E Sato; K Goto; Y Katsurada; K Unno; T Takahashi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1981-03       Impact factor: 1.645

5.  [In vivo localization of monoclonal antibody A-7 to human colon cancer inoculated into nude mice].

Authors:  M Takahashi
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1985-06

6.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

7.  Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody.

Authors:  Y Hashimoto; M Sugawara; T Masuko; H Hojo
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.

Authors:  V Raso; J Ritz; M Basala; S F Schlossman
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

9.  Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells.

Authors:  H E Blythman; P Casellas; O Gros; P Gros; F K Jansen; F Paolucci; B Pau; H Vidal
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962
  9 in total
  1 in total

1.  Immunohistochemical detection of biotin-labeled murine monoclonal antibody in nude mice transplanted with human colon cancer.

Authors:  T Yokota; T Takahashi; T Yamaguchi; K Kitamura; K Sawai
Journal:  Gastroenterol Jpn       Date:  1989-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.